- Oops!Something went wrong.Please try again later.
The adverse impact of the COVID-19 pandemic continued for Medical - Generic Drugs players in the first half of 2021. Uncertainty still lingers with the prevalence of the Delta variant in the United States and other important markets. Although pricing pressure in North American and European markets is stabilizing, it is still hurting the top line of generic drugmakers.
A recovery is expected in the second half of 2021, primarily owing to the easing of prior restrictions and ramped-up vaccinations. Product launches have been driving revenues of major generic drugmakers higher, which will likely continue in the second half. Teva TEVA is a prominent stock in this industry. Companies like Dr. Reddy's Laboratories RDY, Bausch Health BHC and Amphastar Pharmaceuticals AMPH are poised to beat the COVID-19 challenge on the back of gradual economic recovery in some countries, product launches and other favorable macro factors.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Dr. Reddys Laboratories Ltd (RDY) : Free Stock Analysis Report
Teva Pharmaceutical Industries Ltd. (TEVA) : Free Stock Analysis Report
Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report
Bausch Health Cos Inc. (BHC) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research